Inhibition of mTORC1 Kinase Activates Smads 1 and 5 but not Smad8 in Human Prostate Cancer Cells, Mediating Cytostatic Response to Rapamycin.

Reema S. Wahdan-Alaswad1,2, Kara Bane1, Kyung Song1,8, Dorjee T.N. Shola1,4, Jorge A. Garcia6,7 and David Danielpour1,2,5

1Case Comprehensive Cancer Center Research Laboratories, The Division of General Medical Sciences-Oncology, and the 2Department of Pharmacology and 4Department of Molecular Biology and Microbiology, Case Western Reserve University, at Case Western Reserve University School of Medicine. Cleveland, Ohio

5Department of Urology, University Hospitals of Cleveland, Ohio.

6Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 7Glickman Urological & Kidney Institute Cleveland Clinic, Cleveland, Ohio

Running title: Inhibition of mTORC1 activates Smads 1 and 5 in Prostate Cancer Cells

Key words: BMP4, rapamycin, prostate, Smad1, Smad 5, Smad8, apoptosis

8Current address: College of Pharmacy, Wonkwang University
344-2 Sinyong-dong, Iksan city, Cheonbuk
Republic of Korea, 570-749

Corresponding Author: David Danielpour, Case Comprehensive Cancer Center Research Laboratories, Wolstein Research Building, Room 3-532, 2103 Cornell Road, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106. Phone: 216-368-5670; Fax: 216-368-8919; email: dxd49@case.edu.
ABSTRACT:

Although hyper-activated mTOR is well recognized as being pivotal to prostate cancer growth and progression, the underlying mechanisms by which it promotes such responses remain incompletely understood. Here we show that rapamycin activates Smads 1 and 5 in human prostate cancer cells and tissues through blocking mTORC1 kinase. ShRNA-based gene silencing and gene overexpression approaches reveal that Smads 1 and 5 mediate while Smad8 represses rapamycin-induced cell death and expression of the BMP transcriptional target Id1 in human prostate cancer cell lines. Moreover, such phospho-Smad1/5-mediated rapamycin responses were blocked by LDN-193189 (a BMPRI kinase inhibitor) or Noggin (a BMP antagonist) in LNCaP prostate cancer cells. Likewise, the mTOR kinase inhibitors Ku-0063794 and WYE-354 each enhanced phosphorylation of Smad1/5. Intriguingly, silencing Raptor alone enhanced while silencing Rictor repressed the phosphorylation of Smad1/5, indicating that mTORC1 represses while mTORC2 activates BMP signaling. Immunohistochemical analysis showed increased levels of phospho-Smad1/5 concomitant with suppression of phospho-S6 and Survivin levels in PC3 human prostate cancer xenografts in athymic mice administered rapamycin (i.p., 5 mg/kg/day, 2 to 6 days). Moreover, we show that compared to prostate tumor tissue from untreated patients, levels of phospho-Smad1/5 were significantly elevated in the prostate tumor tissue of high-risk prostate cancer patients who received 8 weeks of the rapalog everolimus as part of a neoadjuvant clinical trial prior to undergoing local definitive therapy by radical prostatectomy. Taken together, our data implicate Smads 1, 5 and 8 as potential prognostic markers and therapeutic targets for mTOR inhibition therapy of prostate cancer.
Introduction

The mammalian target of rapamycin (mTOR) is a 298 kDa serine-threonine kinase plays critical roles in the regulation of growth, survival, protein synthesis, metabolism, and angiogenesis. mTOR is activated predominantly through the Akt signaling pathway (1), and is hyperactivated in many human cancers through either loss of phosphatase and tensin homolog (PTEN) or activation of oncogenes such as PI3K and Ras (2-4). Loss of the tumor suppressor PTEN has been implicated in the development of prostate intraepithelial neoplasia (PIN) (5, 6) and castration refractory prostate cancer (7).

Rapamycin and rapamycin-like analogs (rapalogs) are direct inhibitors of the mTOR complex 1 (mTORC1), which contains Raptor and regulates protein synthesis and cell growth through phosphorylating S6K and 4E-BP1 (8). However, rapamycin does not directly inhibit mTOR complex 2 (mTORC2), which contains Rictor and can activate Akt by phosphorylating Akt at Ser473 (9). Rapalogs inhibit mTORC1 through forming a complex with the immunophilin FKBP12 at a site juxtaposed to mTOR’s kinase domain (10). Rapalogs, such as everolimus (afinitor®, Novartis, New Jersey) and temsirolimus (Torisel®, Pfizer, Inc., New York), are now a standard of care in advanced renal cell cancer patients (11), and their optimal use in treating other solid tumors continues (2, 12-14). Despite some encouraging results, rapalogs have had limited therapeutic success as single agents (15, 16), a phenomenon attributed to several mechanisms including the activation of mitogen signaling through IRS-1 (17) among others (18). Notwithstanding major recent advances in the mTOR field, strategies to fully capitalize on the therapeutic potential of rapalogs are limited by our incomplete understanding of the mechanisms by which mTOR promotes tumor growth and mechanisms of resistance.

Our laboratory provided the first evidence that insulin-like growth factor-I (IGF-I) inhibits transforming growth factor-beta (TGF-β)-induced Smad3 phosphorylation and TGF-β responses through a PI3K/Akt/mTOR signaling pathway (19, 20). We recently reported that IGF-I intercepts signaling by another member of the TGF-β superfamily, namely bone morphogenetic protein (BMP) in human and rat prostate epithelial cell lines through blocking the activation of the transcription factors Smads 1, 5 and/or 8 (21). In the current study, we provide evidence that the cytostatic/apoptotic activity of rapamycin in prostate carcinoma cells is partly mediated through its ability to activate BMP signaling. Intriguingly, Smad8 represses rapamycin-induced activation of
Smads and growth suppression. Analysis of PC3 human prostate carcinoma xenographs in mice treated with rapamycin and human prostate cancer tissues from high-risk prostate cancer patients treated with everolimus as a phase II neoadjuvant trial confirms the in vivo relevance of our in vitro findings, and implicate Smads 1, 5 and 8 as potential prognostic markers for rapalog-based therapeutics.

Materials and Methods

Materials. Stemfactor™ recombinant human BMP4 (cat#03-007) and LDN-193189 (Stemgent, Cambridge, MA); rapamycin, (LC labs, Woburn, MA); anti-phospho(P)-Smad3 antibody (P-Smad1/3/5/8, Cat.#9514); anti-P-Smad-1,5,8 antibody (p-Smad1/5/8, Cat.#9511), anti-Smad1,5 (Cat.#9516), anti-P-S6Ser235/236 ribosomal protein (P-S6) (Cat.#2211), anti-P-Akt (Ser473 (Cat.#9271) Ser308 (Cat.#9275) anti-P-Smad2 (Cat.#3101), anti-Cyclin D1 (Cat.#2926) (Cell Signaling, Beverly, MA); anti-Smad2 antibody (Cat.#66220) (Transduction Laboratories, San Diego, CA); anti-Smad3 (sc-8332), anti-survivin (sc-10811), anti-Smad1 (sc-7965), anti-Cyclin D2 (sc-593), BMPRII (sc-130704) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); DMEM/F-12 (1:1); characterized fetal bovine serum (FBS) (HyClone Inc., Logan, UT); insulin (BioSource International, Camarillo, CA); dexamethasone (Sigma, St. Louis, MO); HTS-466284 (EMD Chemicals, Gibbstown, NJ); and Ku-0063794 and WY-354 (Selleck Chemicals). Lentiviral constructs for sh-scrambled, sh-mTOR, sh-Raptor, and sh-Rictor were obtained from David Sabatini’s laboratory through Addgene, Inc.

Cell culture. The LNCaP, PC3, and DU145 cell lines were obtained from ATCC (Rockville, Maryland) and maintained in either DMEM/F12. The above cell lines were authenticated by ATCC (by DNA profiling, cytogenetic analysis, flow cytometry and immunohistochemistry) and used in experiments within 20 passages. C4-2 and C4-2B were from Dr. Leland Chung (22), and used within 20 passages; they were authenticated by morphology, expression of androgen receptor and prostate specific antigen (by Western blot), and androgen-independent growth. The NRP-152 cell line was generated in our laboratory and maintained in GM2.1 (20, 23).

Western analysis. Cell lysates were prepared and analyzed by Western blot as before (20).

Id-I luciferase reporter assay. Cells were transfected, treated and assayed similarly as before (21).
**Reverse transcriptase-polymerase chain reaction (RT-PCR) and RTqPCR.** These were done as before (19).

**Lentivirus-based gene silencing.** Lentivirus-based stable or doxycyclin-inducible shRNA gene silencing (for Smads 1, 5, and 8 and Raptor, Rictor, mTOR and Id1) were produced and generated as previously described (19, 24) using a multiplicity of infection of 50. Targeting sequences for these shRNA constructs are described in supplemental information.

**Rapamycin xenograph study in vivo.** PC3 cells (3x10^6 in 0.2 ml DMEM: Matrigel [1:1, v/v]) were implanted s.c. on opposing flanks of (6-7 week old) Ncr:NU athymic male mice, and tumors were allowed to reach an average of about 25 mm^2 (L x W). Groups of 5 mice were administrated rapamycin (5 mg/kg, i.p.) or vehicle (25) daily for 2 or 6 days. Tumors were fixed in formalin, embedded in paraffin, and subjected to IHC analysis. All experiments performed and euthanasia protocols are detailed in our institutional IACUC protocol #2008-0067.

**Randomized phase II study of two different doses of everolimus as a neo-adjuvant therapy in patients with high-risk prostate cancer undergoing radical prostatectomy.** Eligible patients were randomized to receive either 5.0 mg or 10 mg everolimus orally every day continuously for 8 weeks. One week after the completion of treatment, all men underwent radical prostatectomy with bilateral pelvic lymph node dissection. Pre- and post-treatment prostate tumor tissue samples were fixed in formalin, embedded in paraffin, and stained for P-Smad1/5/8 or P-S6by IHC.

**For cell viability, Hoechst staining, flow cytometry, cell number assay, PCR primers, MTT assay, retrovirus, lentivirus, real-time-PCR, IHC, microarray analysis.** See Supplementary section.
Results

Rapamycin activates Smads in human prostate cancer cells.

We recently reported that IGF-I inhibits BMP4-induced phosphorylation of Smads 1,5 and/or 8 by activating mTOR in prostate epithelial cell lines (21), suggesting that BMP signaling responses may be involved in the mechanism by which rapalogs repress growth of prostate carcinoma cells. To test this hypothesis, we first evaluated a panel of prostate epithelial cell lines (LNCaP, C4-2, C4-2B, PC3, DU145) for response to the cytostatic activity of rapamycin (by MTT and cell number assay (Fig. 1A,B) and activation of Smads (Western blot with c-terminal phospho-specific antibodies) (Fig. 1C). Rapamycin had cytostatic activity and enhanced P-Smad1Ser463/465, or/and P-Smad5Ser463/465, or/and P-Smad8Ser426/428 (or in short, P-Smad1/5/8) in all those cell lines. However, we were unable to distinguish between the phosphorylation of Smads 1, 5 or 8 by Western blot analysis, as they co-migrate and isoform-specific phospho-antibodies for those Smads were not available. Smad2 was not phosphorylated and Smad3 appeared to be phosphorylated only in PC3 cells, which was the only cell line in this group with detectable expression of Smad3. Levels of total Smads were unaltered by rapamycin, except in PC3 cells in which Smad3 was induced and Smad5 was decreased. Rapamycin did not seem to change the levels of mTOR, PTEN or Akt1 in those cells. The magnitude of Smad phosphorylation by 200 nmol/L rapamycin appeared to correlate with that of growth suppression. Under these conditions (DMEM/F12 + 1% FBS), activation of Smads was weakest in DU145, which is the only cell line in this group that expresses PTEN, suggesting that optimal activation of Smads by rapamycin occurred under conditions where Akt is hyperactivated by the absence of PTEN. Consistent with this possibility, culturing DU145 in higher serum (5% FBS) enhanced the phosphorylation of Smad1/5/8 by rapamycin (Supplementary Fig 1A).

We examined the ability of rapamycin to activate Smads 1, 5 and/or 8 in a dose- and time-dependent manner in LNCaP cells. Cells were treated with rapamycin (0-1000 nmol/L) for 24 h or with 200 nmol/L rapamycin from 0 to 72 h, and then subjected to Western blot analysis for total and phospho-Smad1/5/8, as well as for cyclin Ds 1 and 2 (Fig. 2A,B). Phosphorylation of Smad1/5/8 at 24 h was induced by as low as 12.5 nmol/L rapamycin, was maximal between 100 and 200 nmol/L, and inversely correlated with changes in the cyclin Ds 1 and 2. Rapamycin induced levels of P-Smad1/5/8 by 12 h, with maximal induction by 72 h. We confirmed that rapamycin activated Smad1/5/8 rather than just inducing their phosphorylation under these conditions, by transfecting cells in a parallel experiment with an Id1 promoter-luciferase construct, which contains a number of
BMP response elements (26), and measuring luciferase activity various times later (Fig 2C). As anticipated, Id1 promoter was activated with 12.5 nmol/L rapamycin at 24 h; 200 nmol/L rapamycin activated this promoter by 5-fold after 24 h to 45-fold by 72 h (Fig. 2D). Furthermore, rapamycin induced Id1 mRNA levels by 24 h (Fig. 2E). Similar results were obtained in PC3 and in the non-tumorigenic rat cell line NRP-152 (Fig. 2F, Supplementary Fig. S1B,C); however, in those cell lines rapamycin induced the phosphorylation of Smad1/5/8 by as early as 30 min. Rapamycin significantly enhanced BMP4-induced cell death (Hoechst 33258/Flow cytometry/cell number assays) and activated the Id1 promoter activity (Fig. 2G, Supplementary S2A-D and S3).

Rapamycin-mediated cell death requires Smad1 and Smad5 but not Smad8.

We used a lentiviral delivery system for inducible expression of specific small hairpin (sh) RNAs (24) to efficiently and stably silence expression of Smads 1, 5, 1&5, or 8 by >95% in LNCaP and PC3 cells (Fig. 3A and data not shown). Using those cell lines we assessed which of these Smads were activated by rapamycin (200 nmol/L at 24 h) (Fig. 3B, Supplementary Fig. S4A,B). Our analysis revealed that silencing Smads 1 and 5 but not Smad8 repressed the levels of P-Smad1/5/8 activated by rapamycin, suggesting that rapamycin activates both Smad1 and Smad5, but not Smad8. Silencing Smads 1 or 5 also repressed activation of Smad3 by rapamycin in PC3 cells, suggesting that Smads 1 and 5 may be essential for the activation of Smad3 by rapamycin. Intriguingly, blocking Smad8 enhanced rapamycin-induced Smad activation (including Smad3 in PC3 cells), indicating that Smad8 functions as a negative regulator of Smad1 and 5 by rapamycin. Similarly, we observed that sh-Smad1 and sh-Smad5 each suppressed rapamycin-induced Id1 promoter activity, whereas sh-Smad8 enhanced such activity (Fig. 3C). Moreover, sh-Smad1- and sh-Smad5- cells were less responsive to rapamycin than were the sh-LacZ control cells, as measured by changes in cell viability (trypan blue dye exclusion), fraction of adherent cells (Coulter counter), and induction of Id1 promoter activity (Fig. 3C-E, Supplementary Fig. S5). In contrast, Smad8-silenced cells showed increased sensitivity to rapamycin with respect to the above responses. A similar pattern of Smad dependence on cell death was observed with BMP4; however, silencing either Smad1 or Smad5 alone completely reversed BMP-induced cell death (Fig. 3d). In contrast, silencing of Smads 1, 5 or 8 each alone did not significantly reverse BMP4-induced Id1 promoter activity (Supplementary Fig. S5).

Overexpression of Smad1 or Smad5 enhances Rapamycin-induced Id1 promoter activation and cell death in LNCaP cells.
Based on the above results, we efficiently over-expressed Smad1, Smad5, and Smad8 using the pLPCX retrovirus vector in LNCaP and PC3 cells (Fig 4A, data not shown) to test whether those Smads enhance rapamycin’s ability to promote cell death and/or induce the Id1 promoter. The stable cell lines were treated with rapamycin (200 nmol/L, overnight) and analyzed by Western blot, Id1 promoter activity, or cell death (Fig. 4B-D, Supplementary Fig S6a-c). Overexpression of Smad1 and Smad5 enhanced rapamycin-induced activation of Smads, Id1 promoter activity and cell death, whereas overexpression of pLPCX-Smad8 diminished such responses in LNCaP cells (Fig 4). Similar results were observed in PC3 cells over-expressing Smad1, Smad5 and Smad8 (Supplemental Fig. S6). Taken together, these data support that both Smad1 and Smad5 play an important role in mediating rapamycin-induced cell death, whereas Smad8 functions as a negative regulator of this response.

**BMPRI kinase activity is involved in cellular responses to rapamycin.**

Since rapamycin promotes the activation Smads 1 and 5, which are activated by BMP, we examined whether inhibition of BMPRI would abrogate rapamycin’s ability to activate Smad, induce Id1 luciferase promoter activity and/or promote cell death. We examined the above activities in prostate cancer cell lines pre-treated with a selective kinase inhibitor (LDN-193189) of BMP type I receptors (ALK2, ALK3, and ALK6) (27) or a selective kinase inhibitor (HTS-466284) of TGF-β type I receptors (ALK4, ALK5, ALK7) (28). PC3 cells were treated with LDN-193189 (500 nmol/L) or HTS-466284 (2 μmol/L) 2 h prior to 20 h treatment with rapamycin (200 nmol/L) and then subjected to Western blot analysis (Fig. 5A). As in Fig.1a, rapamycin (200 nmol/L) induced expression of both P-Smad1/5/8 (top band) and P-Smad3 (lower band). LDN-193189 repressed activation of Smad1/5/8 (top band), and also repressed P-Smad3 levels, whereas HTS-466284 blocked P-Smad3, and the combined treatment with both inhibitors abrogated all P-Smads. The concentration of each inhibitor was chosen based on the minimal concentration that selectively and efficiently inhibited the activation of Smads by BMP4 or TGF-β. That 500 nmol/L LDN-193189 weakly blocked activation of Smad3 by TGF-β1 (27), suggested that activation of Smad3 by rapamycin is dependent on the kinase activity of a BMP type I receptor. Similarly, we treated the same panel of cell lines with variable concentrations of LDN-193189 (0-500 nmol/L) 2 h prior to a 70 h treatment with 200 nmol/L rapamycin, and then measured the total adherent cells using a Coulter...
counter (Fig. 5B, Supplementary Fig. S7A,B). Inhibition of BMPRI kinase activity by LDN-193189 reversed rapamycin-induced cell death in all cases.

We next examined whether LDN-193189 could block rapamycin’s ability to induce Id1 mRNA or Id1 transcriptional regulation. Semi-quantitative RT-PCR (Fig. 5C) and real-time quantitative PCR (Fig. 5D) was used to assess the ability of BMPRI inhibitor to suppress rapamycin-induced levels of Id1 mRNA and cell death in LNCaP cells. Rapamycin induced expression of Id1 mRNA by 6-fold as determined by real-time PCR (RTqPCR), and LDN-193189 was able to fully suppress rapamycin-induced Id1 mRNA. Similarly, BMP4 was able to enhance Id1 mRNA levels by 20-fold, and when combined with rapamycin this activity was heightened to 42-fold, whereas inclusion of LDN-193189 abrogated such induction. The ability of rapamycin to induce the Id1 promoter activity (Fig. 5E) or cell growth (Fig. 5F) in LNCaP cells was fully and partially reversed by LDN-193189 and HTS-466284, respectively, supporting that activation of the BMPRI kinase is critical to activation of the Id1 promoter or growth suppression by rapamycin.

Next, we examined the role of Id1 induction in growth suppression by rapamycin in LNCaP and DU145 cells by silencing Id1, using previously described shRNAs (21). Cells were infected with either vehicle control pLKO.1-shGFP or pLKO.1-shId1#1 for 48 h prior to a 3 day treatment with rapamycin (200 nmol/L) and/or BMP4 (5 ng/ml), and then analyzed by Western blot for loss of Id1 and changes in both cell number and morphology (Fig. 5G, Supplementary Fig. S7C & S8). We found that silencing Id1 alone suppressed cell growth, but did not reverse rapamycin-induced cell death in either cell line. Taken together, these data support that Id1 induction does not mediate growth suppression by rapamycin.

**Rapalogs enhance levels of phospho-Smad1/5/8 in human prostate cancer tissues, correlating with loss of both mTOR activity and survivin expression.**

Complementing our cell culture studies, we next addressed whether rapamycin would affect Smad activation in vivo. Here PC3 cells (3x10^6 cells) were implanted s.c. in athymic nude male mice and once tumors were evident (~100 mm³), animals were administered daily with either vehicle or rapamycin (5.0 mg kg⁻¹) by i.p. for either 48 h or 6 days. Tumors were then fixed in formalin and processed for IHC analysis of P-Smad1/5/8, P-S6 and survivin expression (Fig. 6A). Administration of rapamycin for 2 days clearly enhanced staining for P-Smad1/5/8 expression and suppressed that for P-S6 and survivin, with greater effects by 6 days. H-score analysis (% positive stained cells x
intensity of staining \{0-3\}), providing statistically significant and quantifiable changes in the pattern of expression (Fig. 6B).

To show the relevance of these findings in humans, we utilized radical prostectomy tumor tissue sections from a phase II clinical trial in which patients with newly diagnosed high-risk prostate cancer were administered everolimus (5 or 10 mg/daily orally) continuously for 8 weeks before undergoing radical prostatectomy. At the time of conducting these experiments, prostate cancer tissue sections from 6 patients were available. Tumor tissue specimens were evaluated for P-Smad1/5/8 and P-S6 via IHC (Fig 6C, Supplementary Fig. S9). We compared these results side-by-side with those from a larger (22 biopsy cores) and a comparable (localized prostate adenocarcinoma stages II-III) cohort of non-treated human prostate tumor tissues in a microarray (PR8011 series) obtained from US BioMax, Inc. H-score analysis was used to evaluate the relative expression of P-Smad1/5/8 and P-S6 in the non-treated control group (n=22) against the everolimus treatment group (n=6) (Fig 6D). Although the sample size (n=6) of this ongoing clinical trial was small, statistically significant differences in relative levels of P-S6 and P-Smad1/5/8 between the everolimus-treated and non-treated groups were generated, with reduced P-S6 levels and increased P-Smad1/5/8 levels in the everolimus group compared to the untreated group. Our data suggest that 6/6 (100%) of patients responded to everolimus treatment by loss of P-S6 and also showed enhanced P-Smad1/5/8 expression, supporting that suppression of mTOR by everolimus enhanced the activation of Smad1/5/8. Although levels of P-Smad1/5/8 staining was weakest the tumor with lowest Gleason Score \[4 + 3\] and the highest level of P-Smad1/5/8 staining occurred in the tumor with the greatest Gleason Score \[5+ 4\], Student’s t-test (two-tailed) did not show any statistically significant correlation (either positive or reverse) between P-Smad1/5/8 staining versus PSA levels, PSA velocity or doubling time (during everolimus treatment), or post-operative PSA levels (Supplementary Table I). Once this trial is completed, all specimens will be re-analyzed in similar fashion and also with the inclusion of Id1 staining, and proliferative, apoptotic and epithelial-mesenchymal transition markers.

**Mechanism of Smad1/5 activation by rapamycin.**

Although selective for mTORC1, prolonged treatment with rapamycin is known to disrupt the function of both mTORC1 and mTORC2 (29). The recent availability of selective mTOR kinase inhibitors, such as Ku-0063794 (30) and WYE-354 (31), which target both mTORC1 and mTORC2, enabled us to test whether targeting the mTOR kinase domain would also induce P-Smad1/5. In a
side-by-side comparison with optimal doses of rapamycin for Smad activation, we showed that each mTOR inhibitor activates Smad1/5 more effectively than does rapamycin (Fig. 7A). Probing the blot for P-Akt<sup>Ser473</sup> and P-S6 supports that rapamycin selectively suppresses the mTORC1 complex, whereas each of the mTOR kinase inhibitors targeted both mTORC1 and mTORC2. More interestingly, each kinase inhibitor elevated the levels of P-Akt<sup>Thr308</sup> more effectively than rapamycin, suggesting that each mTOR complex is involved in negative feedback control of PI3K and Akt.

Rapamycin appears to activate Smads through two distinct mechanisms: an early one occurring by 30 min of stimulation, and another one requiring ≥12 h (Fig. 2B,F, Supplementary Fig. S1B). To examine whether induced secreted or activation of BMPs may explain the delayed activation of Smads by rapamycin, we co-treated LNCaP cells with Noggin, a secretory protein that binds to and neutralizes BMPs (32). Addition of Noggin robustly inhibited both rapamycin-induced and Ku-0063794-induced P-Smad1/5, although Noggin more completely inhibited P-Smad1/5 induced by BMP4 (Fig. 7B), suggesting that rapamycin-activated Smad1/5 is at least partially dependent on the expression and/or activation of BMP ligand.

We examined the role of each mTOR complex in controlling phosphorylation of Smad1/5 in LNCaP cells by infecting them with lentiviruses carrying shRNAs selective for mTOR, Raptor or Rictor. Sh-Raptor significantly elevated levels of P-Smad1/5, whereas sh-Rictor robustly repressed expression of P-Smad1/5 (Fig. 7C). In contrast, sh-mTOR minimally altered levels of P-Smad1/5, consistent with the opposing effects of mTORC1 and mTORC2 on activation of P-Smad1/5. Moreover, sh-Rictor repressed the induction of P-Smad1/5 by rapamycin (Fig. 7C).

The potential mechanism by which mTORC1 represses Smad1/5 was next investigated. Affymetrix microarray analysis of gene expression changes ≥1.3-fold in LNCaP cells following a 24 h treatment with 200nM rapamycin revealed a 1.5-fold induction of BMPRII mRNA (confirmed by RT-PCR, Supplementary Fig. S10). However, rapamycin did not alter the expression of other mRNAs coding for proteins known to be involved in activation of Smads (data not shown). Western blot analysis confirmed a small increase in BMPRII protein levels by 200 nM rapamycin but not by Ku-006379 or WY-354 (Fig. 7A), suggesting that elevated expression of BMPRII does not promote elevation of P-Smad1/5/8 by the mTOR kinase inhibitors. An alternative possibility that mTORC1 directly intercepts the BMP signaling pathway was considered by exploring whether mTOR could directly bind to BMPRII or to Smads 1, 5, or 8. For this, we transfected HEK293 cells with Myc-mTOR along with expression constructs for Flag-Smad1, Flag-Smad5, Flag-Smad8, Flag-BMPRII or pCDNA3 empty vector control (Fig. 7E). Anti-Flag M2 pulled down Myc-mTOR in cells
transfected with Flag-Smads 1, 5, 8 or BMPRII, but not with an empty vector. The greatest pull-down occurred with BMRII and Smad8. These data suggest that mTORC1 represses BMP signaling by a physical association with BMRII as well as with Smads 1, 5 and/or 8.

Discussion

The discovery of rapamycin as an anticancer agent provided enormous impetus to identify its target, mTOR, which was later shown to be a key regulator of protein synthesis, cell metabolism and cell growth. mTOR is activated by mitogenic signals through the receptor tyrosine kinase/PI3K/Akt pathway (33). Importantly, Akt and mTOR are hyperactivated in many cancers including prostate cancer, principally through loss of PTEN and activation of PI3K (34, 35). However, the underlying molecular mechanism(s) by which mTOR promotes the pathogenesis of prostate cancer remain incompletely understood. Despite strong evidence for hyperactivated mTOR in tumor growth, most cancers show limited growth suppression by rapalogs (16), attributed largely to reversal of the negative feedback of mTORC1 on IRS-1 and enhanced activation of Akt (1, 17). While mTORC2 has been shown to be critical to the development of prostate tumors in PTEN knockout mice, mTORC2 is not critical for growth of already established human prostate tumor cells (36).

We suggest that components of the BMP and TGF-β signaling pathways, particularly the expression of Smads 1, 5 and 3 may be critical to the anti-tumor activity of mTOR inhibitors. Our recent report that IGF-I abrogates BMP4 signaling through activating mTOR (21), provided the first functional connection between activation of mTOR and subsequent loss of the tumor suppressor function of BMP4 in prostate cancer cells, and suggested that suppressing mTOR signaling may restore tumor suppression by BMP4. Our current study here extends those findings and provides the first direct evidence that rapalogs induce the activation of Smads 1 and/or 5 in human prostate cancer cells in culture, in tumor xenografts and in human prostate cancer tissues. Our cell culture studies support that such Smad activation is also associated with suppression of mTORC1’s function, and requires Smad1, Smad5 and the kinase activity of a BMP type I receptor (ALKs 2, 3 and/or 6); however, Smad8 represses such activation. Moreover, we show that Smad1, Smad5 and the BMP type I receptor play critical roles in the ability of rapamycin to suppress growth or induce apoptosis, whereas Smad8 reverses rapamycin-induced growth suppression. Furthermore, we show that the
mTOR kinase inhibitors, Ku-0063794 and WY-354 are more effective than rapamycin in activating Smad1/5. While our silencing data shows that mTORC1 and mTORC2 have opposing roles in the activation of Smad1/5, use of novel mTORC1/2 dual kinase inhibitors thereby suggests that the suppression of mTORC1 kinase is critical to activation of Smad1/5.

Here we also provide some insight towards understanding the mechanism by which rapamycin activates Smads 1 and 5, as illustrated by our model in Fig. 7F. Use of Noggin, a selective BMP antagonist, suggests that mTOR kinase inhibitors activate Smad1/5 at least partly through a BMP ligand-dependent mechanism. Affymetrix gene expression analysis shows that rapamycin elevated levels of BMPRII but not BMP mRNAs or other known activators of BMP signaling; however, the inability of two selective mTOR kinase inhibitors to elevate BMPRII suggests that BMPRII may not be a primary target of the inactivation of mTOR. The inability of Noggin to completely reverse the activation of Smads by rapamycin or Ku-0063794 supports that suppression of mTOR activates BMP receptors through both BMP ligand-dependent and -independent mechanisms. While relative to BMP4, rapamycin (or Ku-0063794) does not as robustly activate Smad1/5 (Fig. 7B) or the Id1 promoter (Fig. 4C, 5C-E), rapamycin significantly (about 2-fold) enhanced the Id1 promoter activity in presence of 4 ng/ml BMP4 (Fig. 5D,E), a level saturating for activation of the Id1 promoter. These results suggest that rapamycin activates BMP receptor signaling through a mechanism that also is not entirely dependent on the induced expression or activation of a BMP ligand, since the net effect of rapamycin + BMP4 would at best be additive. Our data showing that BMPRII co-immunoprecipitates with mTOR (Fig. 7E) suggests an alternative mechanism in which rapamycin activates Smad1/5 by reversing a more direct suppression of BMPRII by mTORC1 (Fig. 7F). While we show that antagonizing BMPRII kinase with LDN-193189 reverses the cytostatic action of rapamycin, supporting that BMP receptor signaling mediates or is critical to such cytostatic response by rapamycin, the signal(s) downstream BMP receptors that mediate such a response remains to be defined.

A recent pharmacodynamic study of rapamycin in patients with intermediate- to high-risk prostate cancer (daily doses of 3 mg rapamycin administrated for 14 days) reported repression of tumoral levels of P-S6 and increased nuclear expression of p27, with no significant difference in the expression of key proliferative and apoptotic markers (P-Akt^{Ser473}, Ki-67, cleaved caspase-3)(37). Although P-Akt^{Ser308} levels were not assessed, it is unlikely that such resistance to tumor suppression by rapamycin was through relieving the negative feedback of mTOR via p70S6K, as rapamycin did not activate IRS-1 in those tumors. It is possible that the course of treatment was too short for
detecting significant changes in the above markers. While the duration of our neoadjuvant trial was 4
times longer and our data support that everolimus robustly activates Smad1/5, there is no evidence at
this time that tumor burden was suppressed. Further work will also be necessary to assess if
everolimus can improve surgical success by inhibiting inflammation and/or micro-metastases.

Despite the importance of mTOR in preclinical models, the above clinical studies and others
suggest that rapalogs activate a number of potential compensatory mechanisms in prostate tumors.
Here we provide two of such compensatory mechanisms. Our findings suggest that BMP Smads also
activate other oncogenic signals (i.e., Id1 (21)) that may counteract the therapeutic efficacy of
rapalogs and mTOR kinase inhibitors. Another likely compensatory mechanism well known to be
activated by rapamycin is autophagy (38), a mechanism of cell survival activated in response to
metabolic stress (39). Although autophagy initially promotes cell survival through inhibiting
apoptosis, sustained autophagy by rapamycin and/or in combination with other cellular stresses may
favor the induction of apoptosis (40, 41). This may provide at least part of the mechanistic basis for
the enhanced therapeutic efficacy of rapalogs when combined with autophagy inducers such as
PI3K/Akt inhibitors (42), radiation (43) or anti-androgens (44). Our microarray expression data
suggests that rapamycin activates the androgen receptor signaling pathway, as shown by the
upregulation of many androgen-regulated genes (Supplementary Fig. S10B); this is consistent with a
recent report that an mTOR/PI3K dual kinase inhibitor activates the androgen receptor (45). Two
recent articles published in Science shed light on a potential mechanism for this compensation (46,
47). Both group identified Grb10 as an important direct substrate of mTOR kinase, and showed that
mTOR kinase phosphorylates Grb10 by enhancing Grb10’s ability to bind to and repress receptor
tyrosine kinases. Thus, suppressing mTOR may activate AR through relieving the suppressive effect
of Grb10 on the activation of PI3K/Akt by RTKs (Fig. 7F). Activated PI3K/Akt has been reported to
stabilize and thus activate AR (48) through FOXO3a (49). While the effort to develop mTOR kinase
inhibitors that intercept both mTORC1 and mTORC2 was partly fueled by the incentive to minimize
the compensatory feedback activity of rapamycin, we show that such mTORC1/mTORC2 kinase
inhibitors are instead more effective that rapamycin in phosphorylating Akt at Thr308, albeit being
more effective inhibitors of the phosphorylation of Akt at Ser473 (Fig. 7A).

Given substantial evidence for the oncogenic function of BMP and TGF-β signaling in a
number of late-stage cancers including prostate and breast cancer (50), activation of BMP Smads may
contribute to reduced therapeutic efficacy of rapalogs in androgen-refractory, metastatic prostate
cancer. If so, combined therapeutics with rapalogs and a BMPRI kinase inhibitor (i.e., LDN-189193) may prove efficacious for such cancers. Further research is thus warranted to more fully explore the roles of BMRII and well as Smads 1, 5 and 8 as prognostic markers and therapeutic targets of rapalog- or mTOR kinase inhibitor-based neoadjuvant modalities.

**Figure Legends**

**Figure 1.** Rapamycin-mediated cell death and Smad activation in prostate cancer cell lines. A, Effect of various doses of rapamycin for 72 h on the viability LNCaP, C4-2, C4-2B, PC3, DU145 cells was assessed by a microtiter MTT assay. B, Effect of rapamycin (200 nmol/L) on changes in cell growth was enumerated using a Coulter counter. C, Effect of rapamycin (200 nmol/L, 24 h) on activation of Smads was assessed by Western blot analysis using three different phospho-specific antibodies to the c-terminal phospho-serines of Smads: P-Smad2\textsuperscript{Ser465/467}, P-Smad1/3/5/8, and P-Smad1/5/8, the latter two of which allowed for identification of P-Smad3\textsuperscript{Ser423/425} (lower band) from p-Smad1/5\textsuperscript{Ser463/465/8Ser426/428} (upper band). The blot was reprobed for expression of total each of the total Smads, Akt and mTOR. Values represent averages of triplicate determinations ± S.E.

**Figure 2.** Characterization of rapamycin induced phosphorylation and activation of Smad1/5/8. Dose-dependent effect of rapamycin (for 24 h) on phosphorylation of Smad1/5/8, repression of cyclin Ds (A) and activation of the Id1 promoter (C) was assessed in LNCaP cells. Time-dependent effects 200 nmol/L of rapamycin on the phosphorylation of Smad1/5/8 (B), activation of the Id1 promoter (D), and induction of Id1 mRNA (E) were assessed in LNCaP cells. F, Time-dependent phosphorylation of Smad1/5/8 by 200 nmol/L of rapamycin was determined in PC3 cells. Combined effects of rapamycin (200 nmol/L) and BMP4 (5 ng/ml) on Id1 promoter activity (28 h treatment, left panel) and apoptosis (72 h treatment, right panel) were assessed in LNCaP cells. Apoptotic cells were enumerated under fluorescence and phase contrast microscopy at 200X following staining them Hoechst dye. In the case of the promoter assay, BMP4 was added 4 h prior to harvesting cells. *Columns*, average of triplicate determinations; *bar*, ±S.E. Data is representative of three independent experiments.

**Figure 3.** Silencing Smad1 and Smad5 repress rapamycin-induced Smad activation, Id1 promoter activity and cell death. A, Smad1, Smad5, and Smad8 were effectively silenced in LNCaP cells by transduction with shRNA lentiviruses. B&C, Impact of silencing endogenous Smads
1, 5, 8 on rapamycin (200 nmol/L, 24 h)-induced activation of P-Smads (B, Western blot) activation of Id1 promoter (C). D&E, LNCaP cells stably expressing shSmad1, shSmad5, shSmad1/5, and shSmad8 were treated with rapamycin (200 nmol/L) for 72 h and examined for apoptosis by Hoechst-33258 dye staining (D) or total adherence cells (enumerated by a coulter counter) (E); cells were treated with BMP4 alone or in combination with rapamycin (E) for comparative analysis. Columns, average of triplicate determinants; bar, ±S.E and experiments were run in triplicates.

**Figure 4. Overexpression of Smad1 and Smad5 enhance rapamycin-induced Smad activation, Id1 promoter activity and cell death in LNCaP cells.** A, Smad1, Smad5, and Smad8 were overexpressed using pLPCX retrovirus in LNCaP cells as shown by Western blot analysis. B, LNCaP-pLPCX-control, -Smads 1, 5 or 8 cells were treated with rapamycin (200 nmol/L) for 24 h and examined by Western blot analysis. C, Stably overexpressing LNCaP-Smads 1, 5, and/or 8 were subjected to Id1 promoter activity following treatment of cells with rapamycin (200 nmol/L) for 24 h prior to BMP4 (5 ng/ml) for 4 h. D, LNCaP-pLPCX-control or -Smad1,-Smad5, and/or -Smad8 stably overexpressing cells were treated with rapamycin (200 nmol/L) for 72 h prior to examining % viable adherent cells. Columns, average of triplicate determinants; bar, ±S.E and experiments were run in triplicates.

**Figure 5. Rapamycin-induced Smad1/5/8 activation, Id1 promoter activity, and cell death requires BMPRI.** A, PC3 cells were treated with either BMPRI inhibitor (LDN-193189 (500 nmol/L) or TβRI inhibitor (HTS466284, 2 μmol/L) 2 h prior to rapamycin (200 nmol/L, 20h) treatment; BMP4 (5 ng/ml) was added 4 h prior to harvesting for Western blot analysis of P-Smads. B, Effect of various doses of LDN-193189 reversing the ability of rapamycin (200 nmol/L, 3 days) to decrease the number of adherent cells as assessed in LNCaP (left) and PC3 (right) cells. C&D, Effects LDN-193189 (500 nmol/L, added 2 h before rapamycin addition) on the ability of rapamycin (200 nmol/L, 44 h) or BMP4 (5 ng/ml, 24 h) to induce Id1 mRNA expression in LNCaP cells, as measured by RT-PCR (C) or real-time quantitative PCR (RT-q-PCR) (D). E&F, LNCaP cells were co-transfected with Id1 promoter prior to treating the cells as described in A and luciferase activity (E). F, Effect LDN-193189 v.s. HTS466284 on reversing the ability of rapamycin (200 nmol/L, 3 days) to decrease growth of LNCaP cells. G, Id1 efficiently silenced in LNCaP cells (LNCaP-shGFP v.s. LNCaP-shId1#1) and in DU-145 cells (DU145-shGFP v.s. DU145-shId1#1) were treated with
rapamycin (200 nmol/L) 2 h prior to BMP4 (5 ng/ml) stimulation for 70 h and the total adherent cells were enumerated with a Coulter counter (bottom). Columns, average of triplicate determinants; bar, ±S.E. and data are representative of three independent experiments.

**Figure 6. Rapalogs enhance P-Smad1/5/8 expression in vivo in PC3 xenografts and in tumors of patients with newly diagnosed localized prostate cancer.** A, Expression of p-Smad1/5/8, p-S6 and survivin were assessed by IHC of PC3 tumor xenografts implanted in (6-7 week old ) Ncr:NU athymic male mice that received either vehicle control (n=5), or rapamycin treatment for 48 h (n=5) or 6 day (n=5) as described in methods (left); staining results were quantified by measuring H-score (% positive stained cells x staining intensity (0-3)) of matched sections (right). B, Expression of p-Smad1/5/8 and p-S6 (by IHC) in prostate tumor sections from patients on a phase II clinical trial who were treated with everolimus (5 mg or 10 mg/day for 8 weeks) as neo-adjuvant therapy in patients with high-risk prostate cancer (n=6), and compared to non-treated control patients with prostate adenocarcinoma stage II-III (n=22) (left); H-score (% positive stained cells x staining intensity (0-3)) of non-treated control matched cores were compared to everolimus (RAD001) clinical trial matched sections (right).

**Figure 7. Mechanism of Smad1/5 activation by rapamycin.** A, LNCaP cells were treated with rapamycin (100 and 200 nmol/L) or various concentrations of selective mTOR kinase inhibitors, Ku-0063794 or WYE-354 for 24 h prior to Western blot analysis for P-Smad1/5/8, P-Smad1/5, P-S6, P-Akt1(Ser 473), P-Akt1(Thr308), and BMPRII. B, Activation of P-Smad1/5 by Rapamycin or Ku-0063794 in LNCaP cells is antagonized by Noggin, a BMP antagonist. Cells were treated with Noggin or vehicle 1 h before a 24 h treatment 200 nM Rapamycin or 800 nM Ku-0063794. C, Silencing Raptor activates Smad1/5 whereas silencing Rictor represses the levels of P-Smad1/5. LNCaP cells were infected with lentivirus expressing sh-scrambled, sh-mTOR, sh-Raptor or sh-Rictor for 24 h, and after an additional 48 h for effective silencing, cells were subjected to Western blot analysis. D, sh-Rictor represses the activation of P-Smad1/5 by rapamycin. Cells silenced as shown in C were treated ± rapamycin (200 nmol/L, 24 h) prior to harvesting for western blot. E, BMPRII and Smads 1, 5 and 8 co-immunoprecipitate mTOR. HEK293 cells were transfected with empty vector (pCDNA3), FLAG-Smad1, FLAG-Smad5, FLAG-Smad8 or Flag-BMPRII along with Myc-mTOR, cells were lysed with RIPA buffer 24 h after transfection, and mTOR was co-immunoprecipitated with anti-Flag IgG1 (M2). F, A Unifying model illustrating how mTORC1 and
mTORC2 control BMP signaling. Also illustrated are recently described compensatory mechanisms of mTORC1 on activation of receptor tyrosine kinases (RTKs), Akt and the AR.

**Acknowledgements.** We thank Tracy Krebs for technical assistance and Dr. Cristina Magi-Galluzzi for help with pathological assessment and critique. This work was supported by NIH grants R01CA102074 and R01CA134878 (D. Danielpour) and the Case Comprehensive Cancer Center P30 CA43703 (for Cytometry and athymic mouse cores). R. Wahdan-Alaswad was supported in part by a pre-doctoral fellowship from Research Oncology Training Grant 5T32CA059366-15 (2009) and a National Research Service Award Individual Fellowship Application 1F31CA142311-01 (2010-2011).

**References:**

Figure 1

A.

B.

C.

Figure 1

A. Viability of different cell lines in response to rapamycin treatment.

B. Adherent cell growth of LNCaP, DU145, and PC3 cells treated with rapamycin.

C. Western blot analysis of phosphorylated Smad proteins and other markers in response to rapamycin treatment.
Figure 2

A. LNCaP

Rapamycin (nmol/L) 0 12.5 25 50 100 200 500 1000

P-Smad1,5,8
Smad 1,5,8
CyclinD1
CyclinD2
β-actin

B. LNCaP

Rapamycin (200 nM) (h) 0 0.5 1 3 6 12 24 48 72

P-Smad1,5,8
Smad 1,5,8
β-actin

C. Id1 promoter

Rel. Luciferase Activity

Rapamycin (nmol/L) 0 0.5 1 3 6 12 24 48 72

D. Id1 promoter

Rel. Luciferase Activity

Rapamycin (h) 0 0.5 1 3 6 12 24 48 72

E. LNCaP

Rapamycin (Days) - 1 2 3 6 -

BMP4 (5 ng/mL) - - + + + +

β-actin

F. PC3

Rapamycin (200 nmol/L) (h) 0 0.5 1 3 6 12 24 48 72

P-Smad1,5,8
P-Smad3
Smad 1,5,8
β-actin

G. LNCaP

Rapamycin (200 nmol/L) BMP4 (5 ng/mL)

Relative Luciferase Activity (Id1 promoter/cmv-ren)

% Apoptosis

BMP4 (5 ng/mL) - - + + + +
Figure 3

A. LNCaP-shRNA

<table>
<thead>
<tr>
<th>sh-Smad1</th>
<th>sh-Smad5</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Smad1</td>
<td>β-actin</td>
</tr>
</tbody>
</table>

sh-Smad8

| + | + | sh-Lac Z | - | + | sh-Smad8 |
| - | + | + | sh-Smad8 | - | - |
| Smad8 | Flag M1 | Smad8 | Flag M1 |

B. LNCaP shRNA

<table>
<thead>
<tr>
<th>sh-LacZ</th>
<th>sh-Smad1</th>
<th>sh-Smad5</th>
<th>sh-Smad8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapamycin (200 nmol/L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-Smad1/5/8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C. Relative Luciferase Activity (nM dpm/cell/well)

D. LNCaP-shRNA

<table>
<thead>
<tr>
<th>% Viability</th>
</tr>
</thead>
<tbody>
<tr>
<td>sh-LacZ</td>
</tr>
<tr>
<td>50</td>
</tr>
</tbody>
</table>

E. LNCaP-shRNA

<table>
<thead>
<tr>
<th>% Viability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
</tr>
<tr>
<td>sh-LacZ</td>
</tr>
</tbody>
</table>
Figure 4

A. LNCaP

B. LNCaP

C. LNCaP

D. LNCaP
**Figure 5**

A. PC3

<table>
<thead>
<tr>
<th></th>
<th>Rapamycin (200 nmol/L)</th>
<th>LDN-193189 (500 nmol/L)</th>
<th>HTS-466284 (2 μmol/L)</th>
<th>BMP4 (5 ng/ml)</th>
<th>P-Smad1,5,8</th>
<th>P-Smad1,5,8</th>
<th>P-Smad3</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

B. LNCaP

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>Rapamycin (200 nmol/L)</th>
<th>LDN-193189 (500 nmol/L)</th>
<th>BMP4 (5 ng/ml)</th>
<th>P-Smad1,5,8</th>
<th>P-Smad1,5,8</th>
<th>P-Smad3</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherent Cell (x 10⁴)</td>
<td>50</td>
<td>25</td>
<td>75</td>
<td>25</td>
<td>50</td>
<td>25</td>
<td>75</td>
<td>25</td>
</tr>
</tbody>
</table>

C. Id1

D. β-actin

E. Relative Luciferase Activity (β-gal promoter/cmVREN)

|                      | LNCaP |]
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

F. Total Adherent Cells x (10⁴)

|                      | LNCaP |]
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
</tbody>
</table>

G. LNCaP-PLKO.1 shGFP | LNCaP-PLKO.1 shId1#1 | DU145-PLKO.1 shGFP | DU145-PLKO.1 shId1#1  |

**E:** *P<0.001

**G:** *P<0.001
Figure 6

A. 

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Immunohistochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG control</td>
<td></td>
</tr>
<tr>
<td>P-Smad 1,5,8</td>
<td></td>
</tr>
<tr>
<td>P-S6</td>
<td></td>
</tr>
<tr>
<td>Survivin</td>
<td></td>
</tr>
<tr>
<td>Vehicle</td>
<td></td>
</tr>
<tr>
<td>Rapa 48h</td>
<td></td>
</tr>
<tr>
<td>Rapa 6 d</td>
<td></td>
</tr>
<tr>
<td>Everolimus (RAD001)</td>
<td></td>
</tr>
<tr>
<td>Oral, 5 - 10 mg/day</td>
<td></td>
</tr>
</tbody>
</table>

B. 

H Score (Intensity x Percentage positive staining)

<table>
<thead>
<tr>
<th>Group</th>
<th>H Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No drug (n=5)</td>
<td></td>
</tr>
<tr>
<td>2 days (n=5)</td>
<td></td>
</tr>
<tr>
<td>6 days (n=5)</td>
<td></td>
</tr>
<tr>
<td>Vehicle</td>
<td></td>
</tr>
<tr>
<td>Rapamycin (IP, 5 mg/kg)</td>
<td></td>
</tr>
</tbody>
</table>

C. 

0 Everolimus (RAD001) oral, 5 - 10 mg/day

8 weeks treatment

Prostatecoomy

Prostate Adenocarcinoma (Localized)

RAD001 Trial

Non Treated

Patient #1

Patient #2

D. 

H Score (Intensity x Percentage positive staining)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>P-S158</th>
<th>P-S6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-treated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n=22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAD001 Trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n=6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 7

A.  

<table>
<thead>
<tr>
<th></th>
<th>DMSO</th>
<th>KU0063794 (nM)</th>
<th>Rap (nM)</th>
<th>WYE-354 (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-Smad1/5/8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-Smad1/5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-S6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-AKT (Ser473)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-AKT (Thr308)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMPRII</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B.  

<table>
<thead>
<tr>
<th></th>
<th>DMSO</th>
<th>Rapamycin (200nM)</th>
<th>KU0063794 (800nM)</th>
<th>BMP4 (5ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-Smad1/5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C.  

<table>
<thead>
<tr>
<th></th>
<th>Sh-Scramble</th>
<th>Sh-mTOR</th>
<th>Sh-Raptor</th>
<th>Sh-Rictor</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-Smad1/5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mTOR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raptor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rictor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D.  

<table>
<thead>
<tr>
<th></th>
<th>Sh-Scramble</th>
<th>Sh-mTOR</th>
<th>Sh-Raptor</th>
<th>Sh-Rictor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapamycin (200nM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-Smad1/5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mTOR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loading Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E.  

Flag-Tagged:  
Vector | Smad1 | Smad5 | Smad8 | BMPRII  

IP: w/ α-Flag | IB: w/ α-Myc  
Input: α-Myc | Input: α-Flag  

mTOR  

F.  

RTKs | BMP  

Akt | mTORC1 | Smad1/5 | mTORC2  

FKBP12 | Rapamycin | GRB10 | BRE | BRE  

Raptor | Smad8 | S6K | BRE | BRE  

Tumor growth | Growth arrest | Id1 | Tumor progression  

Early stage cancer | Late stage cancer
Inhibition of mTORC1 Kinase Activates Smads 1 and 5 but not Smad8 in Human Prostate Cancer Cells, Mediating Cytostatic Response to Rapamycin

Reema S. Wahdan-Alaswad, Kara Bane, Kyung Song, et al.

Mol Cancer Res  Published OnlineFirst March 27, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-11-0615

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2012/03/27/1541-7786.MCR-11-0615.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.